A study published July 4, 2011 in the Canadian Medical Association Journal concluded that smokers who take Chantix, a smoking cessation drug, could increase their risk of heart problems.
The study found that there are “safety concerns about the potential for an increased risk of serious adverse cardiovascular events associated with the use of varenicline among tobacco users.”
The heart problems are the latest in a growing list of concerns raised by patient reports, lawsuits and studies since the drug’s approval in 2006.
The drug could cause changes in behavior, hostility, agitation, depressed mood, suicidal thoughts or actions, according to its warning label. Chantix carries a boxed warning — the U.S. Food and Drug Administration’s most restrictive safety labeling — because of the risk of psychological events.
Chantix has been banned by the Federal Aviation Administration for pilots and air-traffic controllers because it may cause loss of consciousness and blackouts. Truck and bus drivers are also not allowed to take the drug.
Among all this is the apparently deliberate attempt to mislead the public regarding the true nature of Pfizer’s Chantix. What are they not saying?
Guess what? Chantix is an addictive benzodiazepine-based psychotropic anti-anxiety drug.
That’s a mouthful.
Just don’t put it in your mouth.
It might just stop you from smoking – permanently.
Click here for more information about the side effects of psychiatric drugs.